MedTrace Logo

Study of the Impact of Everolimus Treatment on Lymphocytes NK (Natural Killer) Development and Functions for Patients With a Metastatic Breast Cancer (HR+ / HER2/Neu Negative)

NCT02536625 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 62

Last updated 2021-02-04

No results posted yet for this study

Summary

NK (Natural Killer) cells are important in the fight against tumor, especially for the control of cancer metastasis. The purpose of this prospective study is to evaluate the impact on lymphocytes NK functions and development of an everolimus treatment in women treated for a metastatic breast cancer. In particular, the study of lymphocytes NK functions and development under everolimus treatment could permit to validate an early biomarker of the impact of everolimus on these NK cells.

Conditions

Interventions

OTHER

prospective study

Sponsors & Collaborators

  • The Biostatistics and Therapy Evaluation Unit

    collaborator OTHER

  • Institut National de la Santé Et de la Recherche Médicale, France

    collaborator OTHER_GOV

  • Ligue contre le cancer, France

    collaborator OTHER

  • Centre Leon Berard

    lead OTHER

Principal Investigators

  • TREDAN Olivier, MD · Centre Leon Berard

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-10-31
Primary Completion
2019-04-30
Completion
2019-12-31

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02536625 on ClinicalTrials.gov